Scarica l'app Stockscreener
12.54
24.05%
-3.97
Dopo l'orario di chiusura:
12.70
0.16
+1.28%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NVCR Giù?
Forum
Previsione
Precedente Chiudi:
$16.51
Aprire:
$16.5
Volume 24 ore:
5.32M
Relative Volume:
4.15
Capitalizzazione di mercato:
$1.40B
Reddito:
$577.74M
Utile/perdita netta:
$-149.78M
Rapporto P/E:
-8.9571
EPS:
-1.4
Flusso di cassa netto:
$-78.21M
1 W Prestazione:
-22.64%
1M Prestazione:
-26.24%
6M Prestazione:
-52.37%
1 anno Prestazione:
-33.26%
Intervallo 1D:
$12.46
$16.51
Intervallo di 1 settimana:
$12.46
$16.67
Portata 52W:
$12.46
$34.13
Novocure Ltd Stock (NVCR) Company Profile
Nome
Novocure Ltd
Settore
Industria
Telefono
44 (0)15 3475 6700
Indirizzo
NO. 4 THE FORUM, ST. HELIER
Confronta NVCR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
12.54 | 1.82B | 577.74M | -149.78M | -78.21M | -1.40 |
|
ABT
Abbott Laboratories
|
125.64 | 218.92B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.21 | 152.62B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
396.66 | 153.22B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
92.32 | 117.89B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
75.80 | 45.12B | 5.54B | 4.18B | 623.10M | 7.00 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-08 | Iniziato | Ladenburg Thalmann | Buy |
| 2024-12-02 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-10-16 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-08-28 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-08-08 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-08-04 | Iniziato | SVB Securities | Outperform |
| 2023-07-31 | Aggiornamento | Evercore ISI | Underperform → In-line |
| 2023-06-07 | Aggiornamento | Wedbush | Underperform → Neutral |
| 2023-05-16 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-17 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-01-06 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-05 | Reiterato | H.C. Wainwright | Buy |
| 2022-11-29 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-10-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-07-05 | Downgrade | Evercore ISI | In-line → Underperform |
| 2022-05-16 | Iniziato | H.C. Wainwright | Buy |
| 2022-02-08 | Iniziato | Loop Capital | Buy |
| 2022-02-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-01-20 | Aggiornamento | Truist | Hold → Buy |
| 2022-01-03 | Aggiornamento | Evercore ISI | Underperform → In-line |
| 2021-07-01 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-14 | Downgrade | Wedbush | Neutral → Underperform |
| 2021-01-25 | Reiterato | Piper Sandler | Overweight |
| 2020-09-23 | Iniziato | Northland Capital | Outperform |
| 2020-09-18 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-09-17 | Downgrade | Truist | Buy → Hold |
| 2020-06-01 | Ripresa | Oppenheimer | Perform |
| 2020-05-01 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-04-09 | Downgrade | Evercore ISI | In-line → Underperform |
| 2020-03-05 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-07-29 | Aggiornamento | SunTrust | Hold → Buy |
| 2019-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-07-26 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-03-20 | Iniziato | SunTrust | Hold |
| 2018-11-02 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2018-07-16 | Iniziato | Evercore ISI | Outperform |
| 2018-04-18 | Reiterato | Mizuho | Buy |
| 2018-02-23 | Reiterato | Mizuho | Buy |
| 2017-05-24 | Aggiornamento | Wells Fargo | Market Perform → Outperform |
| 2016-07-29 | Reiterato | Wedbush | Outperform |
| 2016-01-19 | Iniziato | Barclays | Underweight |
| 2015-12-02 | Iniziato | Deutsche Bank | Hold |
Mostra tutto
Novocure Ltd Borsa (NVCR) Ultime notizie
Novocure Beat Revenue Expectations As Patient Numbers Grew - Finimize
NovoCure Limited Stock Analysis and ForecastFree Stock Movement Tracking - Autocar Professional
NovoCure Limited (NASDAQ:NVCR) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
NovoCure Ltd (NVCR) Stock: 52-Week Performance Insights and Trading Volume - investchronicle.com
Novocure stock hits 52-week low at 14.17 USD - Investing.com Australia
Novocure Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
Novocure: Steady Ahead of Key Milestones - The Motley Fool
NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
NovoCure Ltd Q2 2025 Earnings: EPS Loss of $0.36 Beats Estimates - GuruFocus
Novocure Ltd earnings beat by $0.02, revenue topped estimates - Investing.com South Africa
NovoCure Ltd SEC 10-Q Report - TradingView
Novocure Reports Second Quarter 2025 Financial Results - Stock Titan
What analysts say about NovoCure Limited stockBreakthrough wealth creation - Autocar Professional
What drives NovoCure Limited stock priceRobust investment performance - jammulinksnews.com
Is NovoCure Limited a good long term investmentUnmatched market gains - jammulinksnews.com
M&T Bank Corp Sells 1,750 Shares of NovoCure Limited (NASDAQ:NVCR) - Defense World
How NovoCure Limited stock performs during market volatilityBreakout Level Watch - Newser
What makes NovoCure Limited stock price move sharplyFree Stock Market Group - Newser
Why NovoCure Limited stock attracts strong analyst attentionFast Growing Stocks - Newser
NovoCure (NASDAQ:NVCR) shareholders are up 4.2% this past week, but still in the red over the last three years - simplywall.st
Teacher Retirement System of Texas Buys 3,123 Shares of NovoCure Limited (NASDAQ:NVCR) - Defense World
Most Volatile Stocks in the US (July 2025) - Investing.com
NovoCure Ltd Stock Price Falls 3.41% Amid Analyst Predictions of 81.88% Upside - AInvest
LADENBURG THALM/SH SH Initiates Coverage on NovoCure (NASDAQ:NVCR) - Defense World
NovoCure stock initiated with Buy rating at Ladenburg Thalmann By Investing.com - Investing.com South Africa
This Circle Internet Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
NovoCure stock initiated with Buy rating at Ladenburg Thalmann - Investing.com
NovoCure stock maintains Buy rating at H.C. Wainwright on positive cancer trial data - Investing.com Nigeria
New Clinical Data: Revolutionary Cancer Therapy Cuts Pancreatic Cancer Pain by 47%, Delays Opioid Use - Stock Titan
Novocure to Present Final Secondary Endpoint Data from the Phase - GuruFocus
NVCR SEC FilingsNovocure 10-K, 10-Q, 8-K Forms - Stock Titan
Novocure to Report Second Quarter 2025 Financial Results | NVCR Stock News - GuruFocus
NovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Demystifying NovoCure: Insights From 4 Analyst Reviews - Nasdaq
NovoCure Limited's (NASDAQ:NVCR) P/S Still Appears To Be Reasonable - simplywall.st
Rhumbline Advisers Has $2.69 Million Stock Position in NovoCure Limited (NASDAQ:NVCR) - Defense World
Novocure’s SWOT analysis: innovative cancer therapy firm faces growth hurdles By Investing.com - Investing.com South Africa
Novocure’s SWOT analysis: innovative cancer therapy firm faces growth hurdles - Investing.com India
NovoCure Ltd (NVCR) Shares Up 4.08% on Jun 6 - GuruFocus
NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial - TradingView
Mackenzie Financial Corp Purchases Shares of 6,820 NovoCure Limited (NASDAQ:NVCR) - Defense World
Insider Sell Alert: Frank Leonard Sells 30,196 Shares of NovoCure Ltd (NVCR) - GuruFocus
Novocure at Jefferies Conference: Expanding Horizons in Cancer Treatment - Investing.com
Ameriprise Financial Inc. Has $682,000 Position in NovoCure Limited (NASDAQ:NVCR) - Defense World
H.C. Wainwright reiterates Buy rating on NovoCure stock after ASCO data - Investing.com Nigeria
NovoCure Ltd (NVCR) Shares Down 7.43% on Jun 2 - GuruFocus
NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial - Yahoo Finance
Novocure (NVCR) Gains Support for Future Launch from Promising T - GuruFocus
Novocure (NVCR) Gains Support for Future Launch from Promising Trial Outcomes | NVCR Stock News - GuruFocus
H.C. Wainwright reiterates Buy rating on NovoCure stock after ASCO data By Investing.com - Investing.com South Africa
Novocure Ltd Azioni (NVCR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.03%
0.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):